Results 101 to 110 of about 2,960,910 (293)

Circulating tumor DNA in early‐stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

EMBO Molecular Medicine, 2015
The availability of blood‐based markers to predict response of a solid tumor to treatment, estimate patient prognosis and diagnose relapse well before clinical symptoms arise, is a long‐standing hope in clinical oncology.
Taija M af Hällström, Maija Puhka, Olli Kallioniemi   +2 more
doaj   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Size-Based and Non-Affinity Based Microfluidic Devices for Circulating Tumor Cell Enrichment and Characterization

, 2016
Circulating Tumor Cells (CTCs) are tumor cells found in cancer patients’ peripheral blood. Enumeration of CTCs can provide prognosis information for cancer management (Cristofanilli et al., N Engl J Med 351(8):781–791, 2004; Cohen et al., J Clin Oncol 26(
Richard J. Cote, Cote, Richard J, Zheng Ao, Datar, Ram H, Kamran Moradi, Moradi, Kamran, Ram H. Datar, Ao, Zheng   +7 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors

JAMA Network Open
ImportanceThe prognosis of advanced pancreaticobiliary tumors is poor. Next-generation sequencing (NGS) of tissue samples is utilized to identify actionable alterations, but there are occasional limitations due to inadequate tissue acquisition. Circulating tumor DNA (ctDNA) is an alternative method, but its correlation with tissue-based NGS remains ...
Mahadevia, Himil, Majeed, Umair, Patel, Jaydeepbhai, Ahmed, Ahmed K., Elhariri, Ahmed, Albelal, Douaa, Rao, Nakka Naga Malleswara, Rachamala, Hari Krishnareddy, Mosalem, Osama, Mukhopadhyay, Debabrata, Jones, Jeremy, Mahadevan, Daruka, Borad, Mitesh J., Ahn, Daniel, Sonbol, Mohamad Bassam, Tran, Nguyen, Mahipal, Amit, Wee Ma, Wen, McWilliams, Robert R., Halfdanarson, Thor R., Kankeu Fonkoua, Lionel A., Bekaii-Saab, Tanios, Mody, Kabir, Babiker, Hani   +23 more
openaire   +2 more sources

Microfilter-Based Capture and Release of Viable Circulating Tumor Cells

, 2017
Microfilters with slot-pore geometry can be used for size-based capture of circulating tumor cells (CTC) from the blood of cancer patients. The slot pore geometry reduces the shear stress that the cells would typically experience during filtration ...
Siddarth Rawal, Zheng Ao, Agarwal, Ashutosh, Datar, Ram H, Ashutosh Agarwal, Ram H. Datar, Rawal, Siddarth, Ao, Zheng   +7 more
core   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA

Journal of Experimental & Clinical Cancer Research, 2018
Hepatocellular carcinoma (HCC) is a highly malignant disease with a poor prognosis and high mortality due to a low early diagnosis rate, resistance to systemic treatments and progression to late-stage liver disease.
Jie Li, Xu Han, Xiaona Yu, Zongzhen Xu, Guangsheng Yang, Bingqi Liu, Peng Xiu   +6 more
doaj   +1 more source

Potential of circulating tumor DNA to refine immunotherapy

, 2023
Circulating tumor DNA (ctDNA) is a noninvasive strategy to disease assessment of minimal residual disease and treatment response for advanced cancer. ctDNA is emerging as a tool for use in clinical practice and informing novel clinical trial designs in ...
Luke, Jason J., Lee, RJ; id_orcid, Rebecca J. Lee, Jason J. Luke   +3 more
core   +1 more source